BioCryst Pharmaceuticals, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2009 | -15.6% | -15.6% | — |
| FY2010 | -51.7% | -51.7% | -30.9% |
| FY2011 | -384.6% | -384.6% | -69.3% |
| FY2012 | 8,608.1% | 8,608.1% | -68.0% |
| FY2013 | 2,673.9% | 2,673.9% | -61.6% |
| FY2014 | -59.7% | -59.7% | -33.0% |
| FY2015 | -90.1% | -90.1% | -35.2% |
| FY2016 | -3,494.6% | -224.4% | -61.4% |
| FY2017 | -78.5% | -61.6% | -36.9% |
| FY2018 | -205.7% | -127.8% | -69.0% |
| FY2019 | -284.7% | -284.7% | -62.1% |
| FY2020 | 949.1% | -182.0% | -54.6% |
| FY2021 | 172.0% | -632.6% | -31.3% |
| FY2022 | 83.9% | 392.4% | -44.9% |
| FY2023 | 49.7% | 148.7% | -43.8% |
| FY2024 | 18.7% | 55.2% | -18.1% |
| FY2025 | -221.4% | -221.4% | 51.3% |